Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s stock price fell 12.3% on Monday . The company traded as low as $39.77 and last traded at $39.77. 36,852 shares traded hands during trading, a decline of 82% from the average session volume of 205,287 shares. The stock had previously closed at $45.33.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.
Check Out Our Latest Stock Report on Jyong Biotech
Jyong Biotech Price Performance
About Jyong Biotech
(
Get Free Report)
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
See Also
Before you consider Jyong Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.
While Jyong Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
